MedPath

In children less than 5 years of age with wheezing, inhaled drugs are given for treatment. This study aims to find out which treatment is better; whether inhaled drugs given daily or only during problematic days.

Phase 4
Conditions
Health Condition 1: J455- Severe persistent asthma
Registration Number
CTRI/2023/07/055096
Lead Sponsor
All India Institute of Medical Science AIIMS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Children aged < 5 years who have

1)= Three episodes of Wheezing/year

2)Symptoms (Cough, wheeze, difficulty in breathing) for >7-10 days during upper respiratory tract infections

3)Between the episodes have cough, wheeze, or heavy breathing (occasional or during play/laughing)

4)Allergic sensitization or atopic dermatitis or food allergy or family history of asthma.

(According to GINA guidelines 2022)

Exclusion Criteria

1)Children requiring Pediatric Intensive Care Unit admission due to wheezing

2)Children with = 2 In-Patient admission or > 3 times Oral corticosteroid administration for wheezing in the past 1 year

3)Children with other co-morbidities such as Gastro-esophageal reflux disease

4)Children with other chronic lung diseases- Cystic fibrosis, Primary ciliary dyskinesia, prematurity,etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Test for Respiratory and Asthma Control in Kids (TRACK) score in children on Intermittent inhaled budesonide therapy in comparison to daily inhaled budesonide therapy.Timepoint: Baseline, <br/ ><br>First month, <br/ ><br>Second month, <br/ ><br>Third month.
Secondary Outcome Measures
NameTimeMethod
1.To compare the frequency of wheezing exacerbation requiring oral glucocorticoids/emergency visit/Hospitalizations <br/ ><br>2.Proportion of episode-free days in both the groups <br/ ><br>3.Cumulative dose of ICS used between both the groups <br/ ><br>4.Frequency of adverse effects between both the groups <br/ ><br>Timepoint: baseline 1st month second month third month
© Copyright 2025. All Rights Reserved by MedPath